MASH: A Progressive Liver Disease Demanding Urgent Action

MASH is a progressive liver disease within the MASLD spectrum, and fibrosis is the strongest predictor of liver related outcomes. In endocrinology, many high-risk patients have silent disease and can progress quickly once significant fibrosis develops. This webinar gives a practical approach to identifying who to assess, how to use noninvasive tests to stratify fibrosis risk, and how to understand the key components of effective management.

This 60-minute webinar was originally presented on 3/19/2026.

Learning Objectives

After attending this webinar, participants will be able to:
1. Define MASH as a progressive disease.
2. Recognize the severe consequences of MASH.
3. Understand the role of hepatic thyroid hormone in MASH and the importance of early patient identification.
4. Describe the importance of effective and timely MASH management.

Agenda

1. MASH definition and progression
2. Why fibrosis drives risk
3. Who to assess in endocrine practice
4. Noninvasive testing approach
5. Referral and shared management
6. Q&A

Intended Audience

This activity is designed for diabetes care and education specialists, including nurses, dietitians, pharmacists, nurse practitioners, clinical nurse specialists, PAs, physicians, and other health care providers interested in staying up to date on current practices of care for people with diabetes and other related conditions.

Sponsor

This webinar is sponsored by Madrigal Pharmaceuticals.

Disclaimer

There is no CE/CME credit for this activity.

Access Period

You will have access to this training for a period of six months after you enroll, or when the activity expires on 3/19/2028 (whichever comes first).

Taher Modarressi, MD, FNLA 
Advocare Princeton Cardiometabolic Health 
Pennington, NJ

Dr. Taher Modarressi is an endocrinologist at Advocare Princeton Cardiometabolic Health in Pennington, New Jersey. He is board certified in endocrinology, diabetes and metabolism, clinical lipidology, obesity medicine, and internal medicine.

He earned his bachelor's degree from Princeton University and his medical degree from NYU School of Medicine, where he was inducted into Alpha Omega Alpha. He completed an internal medicine residency at Massachusetts General Hospital, Harvard Medical School, and then an endocrinology, diabetes and metabolism fellowship at the University of Pennsylvania.

Dr. Modarressi serves on several scientific advisory boards and is active in clinical research and publication. His work focuses on cardiovascular risk reduction across diabetes, obesity, lipid disorders, and emerging MASLD and MASH therapies, including identification and management of MASLD and MASH in cardiometabolic populations and real world uptake of these therapies. He also reviews for multiple journals, including The Journal of Clinical Endocrinology and Metabolism and the Journal of Clinical Lipidology.

Pricing

This webinar is FREE for ADCES members and non-members.

Access Period

You will have access to this training for a period of six months after you enroll, or when the activity expires on 3/19/2028 (whichever comes first).